Compare Salesforce Inc (CRM) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Salesforce Inc vs GSK plc — how do they compare? Salesforce Inc trades at $172.25 (market cap $137.23B), while GSK plc trades at $51.08 (market cap $101.55B). The key difference: Salesforce Inc is the larger of the two by market cap, and GSK plc pays the higher dividend (3.5%). Which is the better fit depends on your goals.
| CRM | GSK | |
|---|---|---|
Market Cap | $137.23B | $101.55B |
Sector | Technology | Health |
52-Week High | $270.25 | $61.18 |
52-Week Low | $150.12 | $36.20 |
Enterprise Value | $167.28B | $122.16B |
Dividend Yield | 1.05% | 3.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Salesforce (CRM) trades at $171.28, showing minimal daily movement (+0.04%) amid recent market volatility. The stock demonstrates strong fundamentals with consistent earnings beats (Q1 2026 EPS of $3.88 vs. $3.13 expected) and robust profitability (77.64% gross margin). Technical indicators show mixed signals with bullish overall sentiment but bearish moving averages, while the stock trades near key support at $170. Recent news highlights AI momentum and market concerns about software sector performance.
CRM presents a compelling investment case with strong analyst support (76.84% buy rating) and significant upside to the $235.90 consensus target. However, investors face risks from sector-wide software selloffs, competitive AI landscape pressures, and the stock's 35% YTD decline requiring careful evaluation of growth sustainability versus current valuation discounts.
GSK trades at $52.29, down 0.93% with neutral technical signals. The company shows strong fundamentals with Q1 2026 EPS beating expectations at $1.24 versus $1.16 forecast. Recent FDA approvals for Utebzi and positive Jemperli trial results highlight pipeline strength. Valuation metrics appear reasonable with P/E of 13.94 and ROE of 36.42%.
GSK presents a balanced investment case with solid profitability and promising drug pipeline offset by mixed analyst sentiment and competitive pressures. The stock offers income potential with 3.46% dividend yield but faces execution risks in drug development and market competition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
